Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis Benjamin MarchandotAdrien CarmonaOlivier Morel Letter to the Editor 15 June 2021 Pages: 689 - 691
Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series Richard C. Becker OriginalPaper 17 August 2021 Pages: 692 - 707
Immature platelets in patients with Covid-19: association with disease severity Amir CohenEmanuel HarariEli I. Lev OriginalPaper 14 September 2021 Pages: 708 - 714
Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic mice Yvonne K. JongejanJeroen C. J. EikenboomBart J. M. van Vlijmen BriefCommunication Open access 30 May 2021 Pages: 715 - 719
LncRNA LSINCT5/miR-222 regulates myocardial ischemia‑reperfusion injury through PI3K/AKT pathway Xueying TongJiajuan ChenHezhong Zhu OriginalPaper Open access 28 June 2021 Pages: 720 - 729
Association between plasmatic oxidative stress and thrombosis in primary antiphospholipid syndrome Camila O. VazBruna M MazettoFernanda A. Orsi OriginalPaper Open access 05 July 2021 Pages: 730 - 737
ST-segment elevation in patients with COVID-19: a systematic review Carlos Diaz-ArocutipaJavier Torres-ValenciaCecilia Cuevas OriginalPaper 01 March 2021 Pages: 738 - 745
Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19 Marco G. MennuniRoberta RollaGiuseppe Patti OriginalPaper Open access 10 June 2021 Pages: 746 - 753
Outpatient management of chronic warfarin therapy at a pharmacist-run anticoagulation clinic during the COVID-19 pandemic Rebecca CopeBriann FischettiNardine Karam OriginalPaper 06 March 2021 Pages: 754 - 758
Can a modified-simplified pulmonary embolism severity index (m-sPESI) be used to predict the need for intensive care in hospitalized COVID-19 patients? Ahmet Kagan AsBurak ErdoluTamer Türk OriginalPaper 12 March 2021 Pages: 759 - 765
COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography Cheryl L. MaierTania SarkerRoman M. Sniecinski OriginalPaper 07 April 2021 Pages: 766 - 771
Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation Elvira GrandoneGiovanni TisciaOn behalf of CSS- COVID OriginalPaper 12 April 2021 Pages: 772 - 778
Second wave of the COVID-19 pandemic: D-dimer levels are not so high anymore Angelo PorfidiaEnrica PorcedduRoberto Pola Letter to the Editor 22 April 2021 Pages: 779 - 781
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19 Marco G. MennuniGiulia Rendathe COVID-UPO Clinical Team OriginalPaper Open access 01 March 2021 Pages: 782 - 790
Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension Mateo Porres-AguilarMarius M. HoeperVictor F. Tapson ReviewPaper 09 April 2021 Pages: 791 - 796
Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial M. VerdoiaH. SuryapranataG. De Luca OriginalPaper 13 April 2021 Pages: 797 - 807
SUPPORT‐AF III: supporting use of AC through provider prompting about oral anticoagulation therapy for AF Hammad SadiqLaboni HoqueAlok Kapoor OriginalPaper 10 March 2021 Pages: 808 - 816
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis Sarah A. NislyAlexandra E. MihmJanine Tillett OriginalPaper 16 March 2021 Pages: 817 - 827
Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors Mary HormeseAlex LittlerKarina Rudenberg OriginalPaper 16 March 2021 Pages: 828 - 835
The outcomes of three-factor prothrombin complex concentrate (3F-PCC) in warfarin anticoagulation reversal: a prospective, single-arm, open-label, multicentre study Hock Peng KohNirmala JaganAilin Mazuita Mazlan OriginalPaper 21 March 2021 Pages: 836 - 847
Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma C. Bravo-PerezM. Fernández-CaballeroF. de Arriba BriefCommunication 01 March 2021 Pages: 848 - 853
Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases Jan Philipp BewersdorfNishita ParmarAlfred Ian Lee OriginalPaper 25 March 2021 Pages: 854 - 862
Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE) Xin ZhangQiyan CaiHong Chen ReviewPaper 05 March 2021 Pages: 863 - 871
Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure Yuyi ChenYonghua ZhangYanhong Chen OriginalPaper 05 March 2021 Pages: 872 - 879
Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin Keyun RenHao GongChutse Wu OriginalPaper 07 April 2021 Pages: 880 - 888
Stroke and presence of patent foramen ovale in sickle cell disease Constantina AggeliKali PolytarchouKostas Tsioufis ReviewPaper 26 February 2021 Pages: 889 - 897
A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer Shuangping LiPengfei GaoYimin Mao BriefCommunication 18 February 2021 Pages: 898 - 903
The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials Gonçalo CostaLino GonçalvesRogério Teixeira OriginalPaper 11 March 2021 Pages: 904 - 913
CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients Ramazan GunduzBekir Serhat YildizOzgur Bayturan OriginalPaper 17 March 2021 Pages: 914 - 924
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients Mark D. MuthiahHuili ZhengMark Y. Chan OriginalPaper 06 May 2021 Pages: 925 - 933
Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction Mohamed Abo-AlyBennet GeorgeKhaled Ziada BriefCommunication 30 November 2020 Pages: 934 - 940
The allergic myocardial infarction dilemma: is it the anaphylaxis or the epinephrine? Pei Zheng TanNicholas W. S. ChewPeter Chang ReviewPaper 05 February 2021 Pages: 941 - 948
Monitoring the therapeutic effect of caplacizumab by von Willebrand Factor activity assays: Proceed with caution Sean G. YatesDakota DeutschNicole De Simone BriefCommunication 27 May 2021 Pages: 949 - 951
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia Megan M. J. BaumanRyan M. NaylorEelco F. Wijdicks ReviewPaper 05 June 2021 Pages: 952 - 961
The relation between acute intracerebral hemorrhage and diffusion-weighted imaging lesions: a meta-analysis Xiang LiBei ZhangMingwu Lou OriginalPaper 30 March 2021 Pages: 962 - 970
Utility of a recurrence prediction tool (DASH score) at a single centre after unprovoked venous thromboembolism: patient uptake of the tool and short term risks of stopping anticoagulation W. Thomas Letter to the Editor 02 February 2021 Pages: 971 - 973
Acute limb ischemia in a patient with Covid-19 pneumonia: a case report Ulfah KartikasariSusanthy DjajalaksanaHeny Martini OriginalPaper 01 April 2021 Pages: 974 - 979
Correction to: Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation Elvira GrandoneGiovanni TisciaOn behalf of CSS-COVID 19 Group Correction 28 April 2021 Pages: 980 - 980
Correction to: Cardiomyocyte microvesicles: proinflammatory mediators after myocardial ischemia? Patrick Malcolm SiegelJudith SchmichPhilipp Diehl Correction Open access 16 September 2021 Pages: 981 - 981